



Scientists including researchers from the University of Florida have discovered additional evidence that generalised vitiligo - a disease that typically causes patches of white skin on the face, neck and extremities that pop star Michael Jackson may have experienced - is associated with slight variations in genes that play a role in the body's natural defences…
Graphene, a carbon sheet that is one-atom thick, may be at the centre of the next revolution in material science. These ultrathin sheets hold great potential for a variety of applications from replacing silicon in solar cells to cooling computer chips…
Two drugs approved for treatment of drug-resistant chronic myeloid leukaemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine…
Circulation of cholesterol is regulated in the brain by the hunger-signalling hormone ghrelin, researchers say. The finding points to a new potential target for the pharmacologic control of cholesterol levels…
Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centres. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO)…
The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago…
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy…
HDTV image taking of Earth-rise
Mouse: I am not afraid